Navigation Links
Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA
Date:7/1/2011

ted in patients taking monoamine oxidase inhibitors (MAOIs) or in patients who have taken MAOIs within the preceding 14 days. NUEDEXTA is contraindicated in patients with a known hypersensitivity to its components.

NUEDEXTA may cause serious side effects, including possible changes in heart rhythm. NUEDEXTA is contraindicated in patients with a prolonged QT interval, congenital long QT syndrome or a history suggestive of torsades de pointes, in patients with heart failure as well as patients with, or at risk of, complete atrioventricular (AV) block, unless the patient has an implanted pacemaker.

NUEDEXTA causes dose-dependent QTc prolongation. When initiating NUEDEXTA in patients at risk of QT prolongation and torsades de pointes, electrocardiographic (ECG) evaluation of QT interval should be conducted at baseline and 3-4 hours after the first dose.

The most common adverse reactions in patients taking NUEDEXTA are diarrhea, dizziness, cough, vomiting, weakness, swelling of feet and ankles, urinary tract infection, flu, elevated liver enzymes, and flatulence.

NUEDEXTA may cause dizziness. Precautions to reduce the risk of falls should be taken, particularly for patients with motor impairment affecting gait or a history of falls.

Patients should take NUEDEXTA exactly as prescribed. Patients should not take more than 2 capsules in a 24- hour period, make sure that there is an approximate 12-hour interval between doses, and not take a double dose after they miss a dose.

These are not all the risks from use of NUEDEXTA. For additional important safety information about NUEDEXTA, please see the full Prescribing Information at www.NUEDEXTA.com.

AVANIR™ is a trademark owned by Avanir Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners

©2011 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Forward Looking
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
8. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
9. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
10. Avanir Pharmaceuticals to Present at Three Conferences in March
11. Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 The Pulmonary Fibrosis Foundation (PFF) ... more than 1,100 patients and families suffering from pulmonary ... (FDA) for the Patient-Focused Drug Development Meeting for Idiopathic ... FDA initiative to seek patient input in order to ... "We applaud the FDA for focusing its ...
(Date:9/16/2014)... 2014 Chindex International, Inc. ("Chindex" or the ... a special meeting of stockholders held today, the Company,s ... Agreement") by and among the Company, Healthy Harmony Holdings, ... Parent is an affiliate of TPG, Shanghai Fosun Pharmaceutical ... , the CEO of the Company. The ...
(Date:9/16/2014)... /PRNewswire-iReach/ -- Dan York has been named ... the RTD ® Advanced Wound Care Dressing, as ... presence in the U.S. Under York,s leadership, GWM Products, ... sales representatives in new sales territories that will complement ... up to 20 sales representatives in major metropolitan areas ...
Breaking Medicine Technology:PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 2PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 3PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 4Chindex Stockholders Approve Merger 2Chindex Stockholders Approve Merger 3GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2
... studies including a pivotal Phase III trial in patients,with ... tablets will be presented at the Annual,Meeting of the ... June 1 - 5, 2007. , On this occasion ... on June 4, 2007. Starting at around 2:00 p.m. ...
... of Eisai's,Commitment to Oncology, WOODCLIFF LAKE, N.J., May ... abstracts covering clinical data about,their oncology pipeline compounds ... of Clinical Oncology (ASCO),annual meeting. ASCO takes place ... reveal a growing and diverse oncology clinical,development program ...
Cached Medicine Technology:Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 2Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 3Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 4
(Date:9/16/2014)... WASHINGTON, DC September 14, 2014 A ... provisional side branch (SB) stenting of true coronary ... standard of care. The DKCRUSH-VI clinical trial is ... stenting. , Findings were reported today at ... symposium. Sponsored by the Cardiovascular Research Foundation (CRF), ...
(Date:9/16/2014)... therapy and radiation therapy as part of breast ... women with hormone-receptor positive (HR+) invasive breast cancer. ... Cancer Center, however, shows that combination may not ... disease. , The results, which Fox Chase ... Oncology,s 56th Annual Meeting on Sunday, September 14, ...
(Date:9/16/2014)... that corn absorbs the right balance of nitrogen, phosphorus ... Purdue and Kansas State University study finds. , A ... the U.S. and other regions showed that high yields ... took up key nutrients at specific ratios - nitrogen ... and potassium at a ratio of 1-to-1. These nutrient ...
(Date:9/16/2014)... Seven heroes who have dramatically improved the ... in New York City on November 6 by World ... recognition and funding program that honors individuals serving vulnerable ... the “Nobel Prize for Child Advocates,” this year’s selection ... benefit children in countries around the world dealing with ...
(Date:9/16/2014)... Who:, The Pulmonary Hypertension Association (PHA), ... Children’s Hospital Colorado are hosting Colorado PH in the ... association that works to find ways to prevent and cure ... affects the functioning of the heart and can lead to ... years. , What:, Colorado PH in the Park 2014 ...
Breaking Medicine News(10 mins):Health News:Results of DKCRUSH-VI trial reported at TCT 2014 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:Boosting global corn yields depends on improving nutrient balance 2Health News:Boosting global corn yields depends on improving nutrient balance 3Health News:World of Children® Award Announces 2014 Honorees 2Health News:World of Children® Award Announces 2014 Honorees 3Health News:World of Children® Award Announces 2014 Honorees 4Health News:World of Children® Award Announces 2014 Honorees 5Health News:World of Children® Award Announces 2014 Honorees 6Health News:World of Children® Award Announces 2014 Honorees 7Health News:World of Children® Award Announces 2014 Honorees 8Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2
... A new study shows that estrogen therapy does not ... postmenopausal women, say researchers //.Previous studies have reported an ... dementia. ,A placebo-controlled trial of estrogen or estrogen ... looked at associated risk for dementia. In the estrogen-only ...
... in your 20s could reduce the risk of developing high ... psychological stress with spikes in blood pressure are more likely ... 40s. ,Specialists say assessing blood pressure changes in response ... person’s future risk of high blood pressure. In a large ...
... shows dogs may be able to anticipate seizures in ... dogs in this study was // licking, often ... and “protective" behavior without aggression. In previous studies, owners ... even prevent their seizures. Some breeds of seizure-alerting ...
... patients consume about 40 milligrams of vitamin C daily ... vitamin C may protect against rheumatoid arthritis. ,Researchers ... 45 and 74. Participants' diets were assessed by using ... in two or more joints for at least one ...
... with a number of other side effects. For some people ... through with it may not even get rid of their ... to delivering chemotherapy. ,Perfusion therapy is the most aggressive ... avoid the toxicity to the rest of the body .Blood ...
... might help protect the eyes against a leading cause of ... // men and women it was found that those ... had a 36-percent lower risk of developing age-related maculopathy than ... have linked consumption of antioxidant vitamins and minerals to lower ...
Cached Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: